G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma

Yuxiang Wang(Memorial Sloan Kettering Cancer Center), Jie Yang(The University of Texas MD Anderson Cancer Center), Aaron T. Wild(Memorial Sloan Kettering Cancer Center), Wei Wu(Memorial Sloan Kettering Cancer Center), Rachna Shah(Memorial Sloan Kettering Cancer Center), Carla Danussi(The University of Texas MD Anderson Cancer Center), Gregory J. Riggins(Johns Hopkins University), Kasthuri Kannan(New York University), Erik P. Sulman(The University of Texas MD Anderson Cancer Center), Timothy A. Chan(Memorial Sloan Kettering Cancer Center), Jason T. Huse(The University of Texas MD Anderson Cancer Center)
Nature Communications
February 26, 2019
Cited by 178Open Access
Full Text

Abstract

Mutational inactivation of ATRX (α-thalassemia mental retardation X-linked) represents a defining molecular alteration in large subsets of malignant glioma. Yet the pathogenic consequences of ATRX deficiency remain unclear, as do tractable mechanisms for its therapeutic targeting. Here we report that ATRX loss in isogenic glioma model systems induces replication stress and DNA damage by way of G-quadruplex (G4) DNA secondary structure. Moreover, these effects are associated with the acquisition of disease-relevant copy number alterations over time. We then demonstrate, both in vitro and in vivo, that ATRX deficiency selectively enhances DNA damage and cell death following chemical G4 stabilization. Finally, we show that G4 stabilization synergizes with other DNA-damaging therapies, including ionizing radiation, in the ATRX-deficient context. Our findings reveal novel pathogenic mechanisms driven by ATRX deficiency in glioma, while also pointing to tangible strategies for drug development.


Related Papers

No related papers found

Powered by citation graph analysis